Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Donepezil Hydrochloride

FDA-approved product (tablet, oral), marketed as Adlarity, Aricept, Aricept Odt and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Donepezil Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Dementia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinesterases
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Donepezil Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Donepezil Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors

    NCT02623764 · start 2015-12

    Registered record
    Registry ID
    NCT02623764
    Conditions
    Alzheimer´s Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2015-12
    Completion
    2019-11
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer´s Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

    NCT02006641 · start 2014-02

    Registered record
    Registry ID
    NCT02006641
    Conditions
    Alzheimer's Disease
    Interventions
    Placebo; Idalopirdine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2016-12
    Enrolment
    858

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionPlacebo; Idalopirdine
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)

    NCT01852110 · start 2013-10-22

    Registered record
    Registry ID
    NCT01852110
    Conditions
    Alzheimer's Disease
    Interventions
    MK-7622; Placebo; AChEI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-10-22
    Completion
    2016-04-11
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionMK-7622; Placebo; AChEI
    PhasePhase 2
    Registry statusTerminated

  • [11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease

    NCT02012595 · start 2013-10

    Registered record
    Registry ID
    NCT02012595
    Conditions
    Parkinson's Disease
    Interventions
    [11C]donepezil PET
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-10
    Completion
    2015-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    Intervention[11C]donepezil PET
    PhaseNot recorded
    Registry statusCompleted

  • Zydena on Cognitive Function of Alzheimer's Disease Patients

    NCT01940952 · start 2013-09

    Registered record
    Registry ID
    NCT01940952
    Conditions
    Alzheimer's Disease
    Interventions
    Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg; Placebo + Donepezil 5mg or 10mg; Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2013-09
    Completion
    Not recorded
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionZydena (Udenafil) 50mg + Donepezil 5mg or 10mg; Placebo + Donepezil 5mg or 10mg; Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
    PhasePhase 3
    Registry statusUnknown

  • Donepezil Effect on Visual Attention and Training

    NCT01738295 · start 2013-01

    Registered record
    Registry ID
    NCT01738295
    Conditions
    Healthy
    Interventions
    Donepezil administration; Placebo administration
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-01
    Completion
    2015-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDonepezil administration; Placebo administration
    PhaseNot applicable
    Registry statusCompleted

  • Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease

    NCT01539031 · start 2012-03

    Registered record
    Registry ID
    NCT01539031
    Conditions
    Alzheimer's Type Dementia
    Interventions
    E2020; E2020
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2015-03
    Enrolment
    351

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Type Dementia
    InterventionE2020; E2020
    PhasePhase 3
    Registry statusCompleted

  • The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD

    NCT01696591 · start 2012-03

    Registered record
    Registry ID
    NCT01696591
    Conditions
    Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Delirium, Dementia, Amnestic, Cognitive Disorders; Mental Disorders
    Interventions
    NEUROSTEM®-AD
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2012-03
    Completion
    2013-09
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases +5 more
    InterventionNEUROSTEM®-AD
    PhaseNot recorded
    Registry statusUnknown

  • Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers

    NCT01461174 · start 2011-11

    Registered record
    Registry ID
    NCT01461174
    Conditions
    Healthy
    Interventions
    Modafinil; Donepezil; Memantine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionModafinil; Donepezil; Memantine
    PhasePhase 1
    Registry statusCompleted

  • A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

    NCT01404169 · start 2011-09

    Registered record
    Registry ID
    NCT01404169
    Conditions
    Alzheimer's Type Dementia
    Interventions
    E2020; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2014-09
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Type Dementia
    InterventionE2020; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

    NCT01478633 · start 2011-09

    Registered record
    Registry ID
    NCT01478633
    Conditions
    Alzheimer's Disease
    Interventions
    Galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-06
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionGalantamine
    PhasePhase 4
    Registry statusCompleted

  • Scopolamine Challenge Study

    NCT01213355 · start 2011-04

    Registered record
    Registry ID
    NCT01213355
    Conditions
    Healthy
    Interventions
    Placebo; Scopolamine; PF-05212377; Scopolamine; PF-05212377; scopolamine; PF-05212377; scopolamine; Donepezil; Scopolamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-08
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPlacebo; Scopolamine; PF-05212377; Scopolamine +6 more
    PhasePhase 1
    Registry statusCompleted

  • Comparative Research of Alzheimer's Disease Drugs

    NCT01362686 · start 2011-04

    Registered record
    Registry ID
    NCT01362686
    Conditions
    Dementia; Alzheimer's Disease
    Interventions
    Donepezil; Galantamine; Rivastigmine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2011-04
    Completion
    2015-10
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Alzheimer's Disease
    InterventionDonepezil; Galantamine; Rivastigmine
    PhaseNot applicable
    Registry statusTerminated

  • A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

    NCT01276353 · start 2011-01

    Registered record
    Registry ID
    NCT01276353
    Conditions
    Alzheimer's Type Dementia
    Interventions
    E2020; E2020
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-01
    Completion
    2012-04
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Type Dementia
    InterventionE2020; E2020
    PhasePhase 2
    Registry statusCompleted

  • A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects

    NCT01097876 · start 2010-04

    Registered record
    Registry ID
    NCT01097876
    Conditions
    Healthy
    Interventions
    PF-04447943 25 mg; Placebo PF
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04447943 25 mg; Placebo PF
    PhasePhase 1
    Registry statusCompleted